Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel Added to ADT plus ARTA in Metastatic Hormone-Sensitive Prostate Cancer
KCT0008726Phase 3
Key facts
- Status
- Recruiting
- Start
- Nov 2023
- Countries
- 1
- Sponsor
- Boryung
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Drugs
- docetaxel
- Conditions
- prostate cancer (PCa)
01
Overview
Phase 3, randomised trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by Boryung. Started Nov 2023; status: recruiting.
02
Design
2 arms- Study design
- Randomized
ADT + ARTA
Standard-of-care regimen with androgen deprivation therapy plus an androgen receptor-targeted agent.
ADT + ARTA + docetaxel
Standard ADT plus ARTA with the addition of docetaxel chemotherapy.
03
Who it enrols
Adult male patients in Korea with metastatic hormone-sensitive prostate cancer eligible for ADT plus ARTA, randomized to receive additional docetaxel or not.
Beyond the preview
Go deeper on KCT0008726.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008726.